Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061672 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
A Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 14
- Study locations
NCT00061672 is a Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma that has completed, run by Abbott. The registered enrollment target is 67 participants, below the 393-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (83% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT00061672, a Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 14
- Study locations
Study Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Conditions Studied
Interventions
- DRUG ABT-510 - Thrombospondin-1 Mimetic
Study Locations (14)
Florida
- The Center for Hematology-Oncology - Boca Raton
- Oncology-Hematology Group of South Florida - Miami
- Cancer Centers of Florida, P.A. - Orlando
Arizona
- Hematology Oncology Associates - Phoenix
- Arizona Clinical Research Center - Tucson
Missouri
- Kansas City Oncology and Hematology Group - Kansas City
- Arch Medical Services, INC. - St Louis
Texas
- MD Anderson Cancer Center - Houston
- Hematology Oncology Associates - San Antonio
California
- USC - Norris Cancer Center - Los Angeles
New York
- Albany Regional Cancer Center - Albany
North Carolina
- Raleigh Hematology Oncology Clinic - Cary
Tennessee
- The West Cancer Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061672
The ClinicalTrials.gov registry entry for NCT00061672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (83% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which ABT-510 - Thrombospondin-1 Mimetic is the first listed.
NCT00061672 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, Missouri.
Frequently Asked Questions
What is clinical trial NCT00061672 about?
NCT00061672 is a clinical study titled "Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma". The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
What is the current status of trial NCT00061672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2003-04.
What conditions does trial NCT00061672 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00061672?
The interventions under investigation include: ABT-510 - Thrombospondin-1 Mimetic (DRUG).
Who is sponsoring clinical trial NCT00061672?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061672 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.